We correlated serum 25-hydroxyvitamin D 3 (25OHD) levels with tumor characteristics and
clinical disease outcome in breast cancer patients and assessed the impact of genetic …

Purpose Treatments for breast cancer, specifically hormonal therapy, accelerate bone loss
(BL) among breast cancer survivors, leading to osteoporosis and an increase in fracture risk …

Identifying women at high risk of osteoporotic fracture from aromatase inhibitor (AI) therapy
for breast cancer is largely based on known risk factors for healthy postmenopausal women …

US9221910B2 - Antibodies against human CSF-1R - Google Patents US9221910B2 - Antibodies
against human CSF-1R - Google Patents Antibodies against human CSF-1R Download PDF …

Early breast cancer is among the most common cancers worldwide. Recent advances
continue to improve outcomes and increase long-term survivorship. However, therapeutic …

Skeletal homeostasis is maintained by spatially coupled and balanced processes of
osteolysis and osteogenesis. Several factors across the breast cancer continuum (eg …

5,202,238 A 4, 1993 Fell, Jr. et al. 5,204.244 A 4, 1993 Fell et al. 5,208,020 A 5, 1993 Chari
et al. 5,416,064 A 5, 1995 Chari et al. 5,635,483. A 6, 1997 Pettit et al. 5,712.374. A 1/1998 …

The objective of this paper is to carry out a systemic review of the literature investigating
issues related to bone health in survivors of breast cancer. Given the fact that only a fraction …

Aromatase inhibitors (AIs) are standard treatments for postmenopausal women with
estrogen responsive breast cancers. The mechanism of AIs, inhibition of the aromatase …

Breast cancer and osteoporosis are common diagnoses in women. Breast cancer survival
has improved due to earlier detection and improved treatments. As most breast cancers are …